Booklet Updates - Lymphoma

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.

Cutaneous T-Cell Lymphoma

• In August 2024, the Food and Drug Administration (FDA) approved denileukin diftitox-cxdl (Lymphir™) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. 

Hodgkin Lymphoma

No updates

Non-Hodgkin Lymphoma

• In February 2025, the Food and Drug Administration (FDA) expanded the indication of brentuximab vedotin (Adcetris®) to include the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.
• In June 2024, the Food and Drug Administration (FDA) expanded the indication of epcoritamab-bysp (Epkinly®) to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
• In May 2024, the Food and Drug Administration (FDA) expanded the indication of lisocabtagene maraleucel (Breyanzi®) to include the treatment of:
  • Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 
  • Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.

The Lymphoma Guide: Information for Patients and Caregivers

• In February 2025, the Food and Drug Administration (FDA) expanded the indication of brentuximab vedotin (Adcetris®) to include the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.
• In June 2024, the Food and Drug Administration (FDA) expanded the indication of epcoritamab-bysp (Epkinly®) to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
• In May 2024, the Food and Drug Administration (FDA) expanded the indication of lisocabtagene maraleucel (Breyanzi®) to include the treatment of:
  • Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 
  • Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.

<​< Previous Page